Century Therapeutics, Inc. (IPSC) | Investment Case

1. Company Snapshot

1.a. Company Description

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies.The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma.It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma.

Century Therapeutics, Inc.was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

Show Full description

1.b. Last Insights on IPSC

Negative drivers behind Century Therapeutics' recent performance include the company's initial Q1 earnings miss, as indicated by a Zacks Consensus Estimate of a loss of $0.31 per share, which was later surpassed by the actual earnings of $0.89 per share. Additionally, the company's failure to meet revenue estimates in its Q4 2024 report, coupled with the lack of a clear growth trajectory, has raised concerns about its future prospects. Furthermore, the recent announcements of upcoming presentations at the EULAR 2025 Congress and the ASGCT 28th Annual Meeting, while potentially positive for the company's pipeline, do not provide immediate relief to investors.

1.c. Company Highlights

Last Price	0.52
Change Percentage	-0.74%
Open	0.52
Previous Close	0.53
Market Cap ( Millions)	45
Volume	197473
Year High	1.74
Year Low	0.34
M A 50	0.54
M A 200	0.55

FCF Yield	-254.80%
Dividend Yield	0.00%
ROE	-11.53%
Debt / Equity	24.53%
Net Debt / EBIDTA	41.56%
Price To Book	0.21
Price Earnings Ratio	-1.93
Price To FCF	-0.39
Price To sales	0.39
EV / EBITDA	-3.04

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference

Nov -25

Source: globenewswire.com

Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov -13

Source: globenewswire.com

Century Therapeutics to Present at Chardan's 9th Annual Genetic Medicines Conference

Oct -14

Source: globenewswire.com

Century Therapeutics to Present at Chardan's 9th Annual Genetic Medicines Conference

Oct -14

Source: globenewswire.com

Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug -22

Source: globenewswire.com

Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug -14

Source: globenewswire.com

All You Need to Know About Century Therapeutics (IPSC) Rating Upgrade to Strong Buy

Jul -21

Source: zacks.com

Century Therapeutics (IPSC) Is Attractively Priced Despite Fast-paced Momentum

Jun -25

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (14.27%)

6. Segments

Allogeneic Cell Therapies

Expected Growth: 14.27%

Century Therapeutics' allogeneic cell therapies exhibit 14.27% growth driven by increasing demand for cancer treatments, advancements in gene editing technologies, strategic partnerships, and expanding pipeline of novel therapies. Additionally, the growing need for more effective and targeted treatments, coupled with favorable regulatory environments, fuels growth in this segment.

7. Detailed Products

Allogenic Cell Therapies

Century Therapeutics develops allogenic cell therapies that utilize healthy donor cells to treat various diseases and disorders.

Autologous Cell Therapies

The company develops autologous cell therapies that use a patient's own cells to treat diseases, reducing the risk of rejection.

Induced Pluripotent Stem Cell (iPSC) Technology

Century Therapeutics utilizes iPSC technology to develop off-the-shelf cell therapies for various diseases.

Gene-Edited Cell Therapies

The company develops gene-edited cell therapies that use CRISPR-Cas9 technology to treat genetic diseases.

Natural Killer (NK) Cell Therapies

Century Therapeutics develops NK cell therapies that utilize the body's natural killer cells to target cancer cells.

8. Century Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Century Therapeutics, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies in the market.

Bargaining Power Of Customers

The bargaining power of customers is low due to the specialized nature of Century Therapeutics, Inc.'s products and services, which limits the ability of customers to negotiate prices.

Bargaining Power Of Suppliers

The bargaining power of suppliers is moderate due to the presence of multiple suppliers in the market, but Century Therapeutics, Inc.'s dependence on a few critical suppliers limits its negotiating power.

Threat Of New Entrants

The threat of new entrants is high due to the growing demand for cell therapies and the increasing interest in the field, which attracts new companies and investors.

Intensity Of Rivalry

The intensity of rivalry is high due to the presence of established players and new entrants in the market, leading to a highly competitive landscape.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	20.68%
Debt Cost	3.95%
Equity Weight	79.32%
Equity Cost	11.19%
WACC	9.69%
Leverage	26.07%

11. Quality Control: Century Therapeutics, Inc. passed 4 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Atara Bio

A-Score: 5.6/10

Value: 7.4

Growth: 8.0

Quality: 7.0

Yield: 0.0

Momentum: 10.0

Volatility: 1.0

1-Year Total Return ->

Eton Pharmaceuticals

A-Score: 4.4/10

Value: 2.2

Growth: 7.1

Quality: 4.6

Yield: 0.0

Momentum: 10.0

Volatility: 2.7

1-Year Total Return ->

Oramed Pharmaceuticals

A-Score: 4.1/10

Value: 7.8

Growth: 4.8

Quality: 3.0

Yield: 0.0

Momentum: 6.0

Volatility: 3.0

1-Year Total Return ->

Century Therapeutics

A-Score: 3.8/10

Value: 9.6

Growth: 5.4

Quality: 5.2

Yield: 0.0

Momentum: 0.5

Volatility: 2.0

1-Year Total Return ->

Biora Therapeutics

A-Score: 3.0/10

Value: 8.8

Growth: 3.4

Quality: 5.2

Yield: 0.0

Momentum: 0.0

Volatility: 0.3

1-Year Total Return ->

Sutro Biopharma

A-Score: 3.0/10

Value: 9.4

Growth: 2.3

Quality: 4.9

Yield: 0.0

Momentum: 0.5

Volatility: 0.7

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

14.43%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

9.69%

Century Therapeutics, Inc. - US15673T1007

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on IPSC

1.c. Company Highlights

Average Quality

Average Growth

Medium Volatility

Earnings Beats

Lower Growth

Fairly Valued

Stable Momentum

Revenues Beats

Weak Momentum

Revenues Miss

Cheaper

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (14.27%)

6. Segments

Allogeneic Cell Therapies

Expected Growth: 14.27%

7. Detailed Products

Allogenic Cell Therapies

Autologous Cell Therapies

Induced Pluripotent Stem Cell (iPSC) Technology

Gene-Edited Cell Therapies

Natural Killer (NK) Cell Therapies

8. Century Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Century Therapeutics, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.52$

Current Price

0.52$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA